SARS-CoV-2 neutralising Affimer

SARS-CoV-2 neutralising Affimer is an **experimental Affimer-based biologic antiviral** developed by **Avacta Group** for the prevention and treatment of **COVID-19**. The active agent consists of engineered **Affimer protein reagents** derived from a small human protein scaffold that are designed to bind the **SARS-CoV-2 spike protein** and **block its interaction with the human ACE2 receptor**, thereby inhibiting viral attachment and entry into host cells. Based on the available information, this program was at a **preclinical or discovery-stage partnering stage** rather than clinical development, with Avacta reporting generation of multiple spike-binding Affimer candidates and seeking a development partner.

Other names

SARS-CoV-2 neutralising AffimerSARS-CoV2 neutralising AffimerSARS-CoV 2 neutralising Affimerneutralising AffimerSARS-CoV-2 spike-binding AffimerSARS-CoV2 spike-binding AffimerSARS-CoV 2 spike-binding Affimer